Pioneering Japan Approval For Daiichi’s Oncolytic Virus In Glioma
But Conditions Apply
Japan grants ground-breaking approval for Daiichi oncolytic virus in brain cancer on condition of additional data. The nod marks another step forward in the firm's strategic global pivot to oncology.
You may also be interested in...
Atuzaginstat targets a bacteria associated with Alzheimer’s disease. The higher of two doses showed a 57% slowing in cognitive decline in the Phase II/III GAIN trial in mild to moderate patients with P. gingivalis infection confirmed by saliva test.
The Consumer Technology Association hopes its newly developed standard for digital therapeutics will clear up industry confusion and encourage the adoption of these treatments. See what Kerri Haresign, director of technology and standards at CTA, said about it here.
Lilly plans a head-to-head study of donanemab versus Biogen’s Aduhelm to see which clears amyloid plaque better and has begun a rolling BLA toward accelerated approval of the Alzheimer’s drug.